血滞通联合匹伐他汀钙对脑梗死患者神经功能指标及血脂水平的影响  

Effects of Xuezhitong Combined with Pitavastatin Calcium on Neurological Function Indexes and Blood Lipid Levels in Patients with Cerebral Infarction

作　　者：刘丽英 邹思璐 查登峰 LIU Liying;ZOU Silu;ZHA Dengfeng(Jingdezhen Second People's Hospital,Jingdezhen Jiangxi 333000,CHina)

机构地区：[1]景德镇市第二人民医院,江西景德镇333000

出　　处：《药品评价》2022年第10期622-625,共4页Drug Evaluation

摘　　要：目的:探讨血滞通联合匹伐他汀钙治疗脑梗死的临床效果及对患者神经功能、血脂水平的影响。方法:选取景德镇市第二人民医院2019年1月至2020年12月收治的脑梗死患者60例,按随机数字表法分为两组,各30例。两组均接受常规治疗,对照组予以匹伐他汀钙治疗,观察组加用血滞通治疗,持续用药1个月。比较两组临床疗效、神经功能、血脂水平、血液流变学指标[全血高切黏度(HBV)、血浆黏度(PV)、全血低切黏度(LBV)]、血管内皮功能[一氧化氮(NO)、内皮素-1(ET-1)]及不良反应发生情况。结果:观察组治疗总有效率较对照组高,差异有统计学意义(P<0.05);观察组治疗后神经功能缺损(NIHSS)评分、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)为(8.52±1.13)分、(1.38±0.21)mmol/L、(3.85±0.52)mmol/L、(2.45±0.39)mmol/L低于对照组,高密度脂蛋白胆固醇(HDL-C)为(1.59±0.26)mmol/L高于对照组,差异有统计学意义(P<0.05);观察组治疗后HBV、PV、LBV分别为(4.89±0.78)mpa·s、(1.41±0.24)mpa·s、(8.11±1.15)mpa·s,均低于对照组(均P<0.05);观察组治疗后NO为(89.82±7.13)μmol/L高于对照组,ET-1为(52.48±5.14)μg/L低于对照组,差异有统计学意义(P<0.05);两组均无严重不良反应发生。结论:血滞通联合匹伐他汀钙可增强脑梗死治疗效果,纠正脂代谢异常,降低血液黏度,减轻血管内皮功能损害,促进神经功能恢复,安全可靠。Objective:To investigate the clinical effect of xuezhitong combined with pitavastatin calcium in the treatment of cerebral infarction and its effect on the neurological function and blood lipid level of patients.Methods:A total of 60 patients with cerebral infarction admitted to Jingdezhen Second People’s Hospital from January 2019 to December 2020 were selected and divided into two groups according to the random number table method,with 30 cases in each group.Both groups received routine treatment,the control group received pitavastatin calcium therapy,and the observation group received xuezhitong therapy for 1 month.The clinical efficacy,neurological function,blood lipid level,hemorheological indexes whole blood high shear viscosity(HBV),plasma viscosity(PV),whole blood low shear viscosity(LBV),vascular endothelial function nitric oxide(NO),endothelin-1(ET-1)and the occurrence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the observation group was higher than that in the control group,the difference was statistically significant(P<0.05).The NIHSS,TG,TC,LDL-C score of the observation group after treatment was(8.52±1.13)points,(1.38±0.21)mmol/L,(3.85±0.52)mmol/L,(2.45±0.39)mmol/L lower than the control group,high-density lipid protein cholesterol(HDL-C)was(1.59±0.26)mmol/L,which was higher than that in the control group,and the difference was statistically significant(P<0.05).After treatment,HBV,PV and LBV in the observation group were(4.89±0.78)mpa·s,(1.41±0.24)mpa·s and(8.11±1.15)mpa·s,which were lower than those in the control group,and the difference was statistically significant(P<0.05).The NO in the observation group after treatment was(89.82±7.13)μmol/L,higher than the control group,ET-1 was(52.48±5.14)μg/L,lower than the control group,the difference was statistically significant(P<0.05);no serious adverse reactions occurred in both groups.Conclusion:Xuezhitong combined with pitavastatin calcium can enhance the therapeutic effect

关 键 词：脑梗死 血滞通 匹伐他汀钙 神经功能 血脂 

分 类 号：R743.3[医药卫生—神经病学与精神病学]